Clinical Trial Search

Primary: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Contraceptive Continuation — 201; 174; 154; 118 Participants — p=0.46

Primary: Predicted Mean Difference in Body Weight From Baseline, by Assigned Dietary Group — -5.7; -2.6; -5.6; -2.3 kg

Primary: Glycemia — 7.1; 7.6 percent of glycosylated hemoglobin

Primary: Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS — 75 mcg daily with BID dosing

Primary: Mental Health or Substance Use Issue Raised in Visit — 32 Participants

Primary: Dose Limiting Toxicity (DLT) - Percentage of Participants With DLT Events — 0; 0 percentage of participants.

Primary: Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation — 4; 5 participants

Primary: Number of Participants With Each Category of Adverse Events in Stage I — 5; 4; 5; 5 Participants

Primary: Change in Interproximal Plaque by Modification of the Quigley-Hein Plaque Index at 14 Days — 0.03; -0.07 score on a scale

Primary: Change in Plasma Glucose — 81.4; 84.2; 54.0 mg/dL — p=<0.001

Primary: The Number and Percent of All Evaluable Patients Who Have Successfully Undergone TORS at Each Interim Analysis. — 54 Participants

Primary: Oxygen Saturation Values Obtained From Pulse Oximetry — 97.6; 95.8; 97; 96 percentage of oxygen saturation (SpO2)

Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 1.93; 2.26; 1.83; 2.58 units on a scale

Primary: Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine — 37; 40.5 pounds